Day 2

Day 2

Saturday, 7 September 2024 (8.00am to 6.30pm)

Session 4 – Moderators: Dr. Anas Hamad & Dr. Hadi Abu Rasheed

7.30am to 8am

Registration

8am to 8.05am

Day 2 Opening Remarks

8.05am to 8.25am

Prevention, Risk Reduction, and Genetics (Abstract 10507): Effects of HPV vaccination on the development of HPV-related cancers: A retrospective analysis of a United States-based cohort.

Dr. Hadi Mohamad Abu Rasheed
Head of the Cancer Awareness and Professional Development Department, Qatar Cancer Society

8.25am to 8.45am

Developmental Therapeutics – Immunotherapy (Abstract 2504): Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies

Dr. SaidDermime
Director for Cancer Translational Research Facility, NCCCR

8.45am to 09.05am

Developmental Therapeutics – Immunotherapy (Abstract LBA2509): Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial

Dr. Shereen Elazzazy
Assistant Director of Pharmacy for Clinical Services, NCCCR

9.05am to 9.25am

Care Delivery/Models of Care (Abstract 1504): A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study).

Dr. Anas Hamad
Director of Pharmacy Department, NCCCR

9.25am to 9.45am

Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract 4003): A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186

Dr. Wamda Abdalla
Medical Oncologist, NCCCR

9.45am to 10am

Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract 4005): NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA)

Dr. Meeloud Aldardouri
Clinical Fellow, Oncologist, NCCCR

10am to 10.15am

PANEL DISCUSSION

10.15am to 10.30am

Coffee Break

Session 5 – Moderators: Dr. Kakil Rasul & Dr. Alaaeldin Shablak

10.30am to 10.50am

Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract LBA4008): Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW

Dr. Kakil Rasul
Senior Consultant Medical Oncologist, NCCCR

10.50am to 11.10am

Gastrointestinal Cancer - Colorectal and Anal (Abstract 3503): Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW

Dr. Waleed Alselwi
Consultant Medical Oncologist, 
King Fahad Specialist Hospital, Dammam, KSA

11.10am to 11.30am

Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract LBA1): Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial)

Dr. Alaaeldin Shablak
Consultant Medical Oncologist, NCCCR

11.30am to 11.50am

Gastrointestinal Cancer - Colorectal and Anal (Abstract LBA3501): Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial

Dr. Mohamed Siralkhatim Hamid
Consultant Medical Oncologist, NCCCR

11.50am to 12:10pm

Gastrointestinal Cancer - Colorectal and Anal (Abstract 108): Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial

Dr. Mai Mostafa
Consultant Medical Oncologist, NCCCR

12:10pm to 12:30pm

Gastrointestinal Cancer - Colorectal and Anal (Abstract 3500): Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET)

Dr. Aleem Akram
Associate Consultant Medical Oncologist, NCCCR

12.30pm to 12.50pm

PANEL DISCUSSION

12.50pm to 1.45pm

Prayer and Lunch Break

Session 6 – Moderators: Dr. Abdulrehman Zar Gul & Dr. Mohamed Riyas

1.45pm to 2.05pm

Genitourinary Cancer - Prostate, Testicular, and Penile (Abstract 5009): A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.

Dr. Hassan Aakel

Medical Oncologist, NCCCR

2.05pm to 2.25pm

Genitourinary Cancer - Prostate, Testicular, and Penile (Abstract 4502): Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).

Dr. Ahmed Abdalhadi

Clinical Fellow, Oncologist, NCCCR

2.25pm to 2.40pm

Head & Neck (Abstract LBA6000): Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.

Dr. Abdulrehman Zar Gul

Senior Consultant Medical Oncologist, NCCCR

2.40pm to 3.00pm

Head & Neck (Abstract 6008): A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.

Dr. Aladdin Kanbour

Consultant Medical Oncologist, NCCCR

3.00pm to 3.15pm

Central Nervous System Tumors N2M2/NOA-20 (Abstract 2000): Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.

Dr. Saju R. Divakar

Senior Consultant Radiation Oncologist, NCCCR

3.15pm to 3.30pm

PANEL DISCUSSION

3.30pm to 3.45pm

Prayer & Coffee Break

Session 7 – Moderators: Dr. Ussama Al Homsi & Dr. Azza Hassan

3.45pm to 4.05pm

Lung Cancer - Non-Small Cell Metastatic (Abstract LBA8503): Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study

Dr. Mohammed Ussama Al Homsi
Deputy Medical Director for Education, Research and Quality, Senior Consultant Medical Oncologist, NCCCR

4.05pm to 4.25pm

Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract LBA4): Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.

Dr. Mohamed Riyas
Senior Consultant Radiation Oncologist, NCCCR

4.25pm to 4.40pm

Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract LBA5): ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

Dr. Shaima Abdelrahim
Clinical Fellow, Oncologist, NCCCR

4.40pm to 4.55pm

Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract LBA8002): BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM) - Results from the ETOP 13-18 trial.

Dr. Muhammed Hajmusa
Clinical Fellow, Oncologist, NCCCR

4.55pm to 5.10pm

Lung Cancer - Non-Small Cell Metastatic (Abstract LBA8505): Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.

Dr. Nabil Omar,
Clinical Pharmacist, NCCCR

5.10pm to 5.30pm

Symptom Science and Palliative Care (Abstract LBA3): Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.

5.30pm to 5.45pm

Symptom Science and Palliative Care (Abstract 12020): A randomized, double-blind controlled trial of medicinal cannabis vs placebo for symptom management in patients with advanced cancer receiving palliative care

Ms. ZEINAB IDRIS
Clinical Nurse Specialist
NCCCR

5.45pm to 6.00pm

Symptom Science and Palliative Care (Abstract 12016): Identifying optimized assessment of nerve damage during chemotherapy.

Ms. RENI ANIL
Clinical Nurse Specialist
NCCCR

6.00pm to 6.20pm

PANEL DISCUSSION

6.20pm

Closing Ceremony

Dr. Mohammed Ussama Al Homsi
Deputy Medical Director for Education, Research and Quality, Senior Consultant Medical Oncologist, NCCCR​​​​​​